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Abstract
Introduction:  The World health Organization declared the goal of hepatitis c virus (hcV) elimination by 2030. Micro-
elimination, which is the reduction of incidence to zero in targeted populations, is less complex and costly and may be 
the first step to prove whether elimination is feasible. a suitable target group are hiV-positive men who have sex with 
men (MsM) because of their high-risk behaviour and high incidence rates. Moreover, hcV monitoring is integrated in 
hiV care. The current hcV monitoring approach is suboptimal and complex and may miss new hcV infections. alternative 
monitoring strategies, based on alanine aminotransferase, hcV-Pcr and hcV-core antigen (hcV-cag), combined with 
immediate direct-acting antiviral (Daa) treatment, may be more effective in reducing new hcV infections.
Methods:  a deterministic mathematical transmission model was constructed representing the Dutch hcV epidemic 
among hiV-positive MsM to compare different hcV monitoring strategies from 2018 onwards. We evaluated the 
epidemiological impact of alternative and intensified monitoring in MsM with hcV. in addition, the cost-effectiveness 
was calculated over a lifetime horizon.
Results:  current hcV monitoring and treatment is projected to result in an incidence of 1.1/1000 person-years, 0.24% 
prevalence, at a cost of €61.8 million (interquartile range 52.2–73.9). compared with current monitoring, intensified 
monitoring will result in a maximum 27% reduction of incidence and 33% in prevalence at an increased cost. conversely, 
compared with current monitoring, targeted hcV-cag monitoring will result in a comparable incidence (1.1/1000 
person-years) and prevalence (0.23%) but will be €1 million cheaper with increased quality-adjusted life year.
Conclusion: Targeted monitoring reduces the hcV epidemic in a cost-saving manner; however, micro-elimination may 
not be obtained by 2030, highlighting the need for harm-reduction programmes.
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Introduction
since the introduction of well-tolerated direct-acting antivirals 
(Daas), the outcome of hepatitis c virus (hcV) treatment has 
dramatically improved. Daa treatment has a 90%–95% sustained 
virological response (sVr), which is associated with reduced 
morbidity [1,2]. since cured individuals cannot transmit hcV, 
Daas may be used as a prevention strategy. This was shown in 
the netherlands, where new hcV infections among hiV-positive 
men who have sex with men (MsM) were reduced by 51% after 
widespread Daa use in 2015 [3,4].
The World health Organization (WhO) shares the optimism about 
Daas as a prevention tool and declared the ambitious target of 
ending hcV as a public health threat by 2030 [5]. To achieve the 
2030 elimination goals, a 90% reduction in new infections, a 90% 
diagnosis rate and a 65% mortality reduction must be obtained. 
Micro-elimination, which is the reduction of hcV incidence to 
zero in targeted populations, can be used as a first step towards 
elimination since it is less complex and less costly [6]. a suitable 
group for micro-elimination are hiV-positive MsM since they 
have high-risk behaviour and are the predominant risk group for 
continuous hcV transmission in several high-income countries. in 
addition, they are a well-defined population and mostly engaged 
in hiV care in which hcV monitoring is integrated [7].
currently, hcV monitoring during hiV care is based on annual 
anti-hcV antibody tests and biannual hepatic transaminases (alT) 
measurements. in addition, hcV-rna monitoring is recommended 
when risk factors (e.g. ongoing injecting drug use [iDU], mucosal 
traumatic sex, ongoing unprotected anal intercourse and recent 
sexually transmitted infections) are present in combination with 
an unexplained elevation of alT levels [8]. currently, guidelines 
advise biannual hcV-rna or hcV-core antigen (hcV-cag) testing 
among hiV-positive individuals with ongoing risk factors regard-
less of alT levels [8].
however, the current monitoring approach has the risk of missing 
new hcV infections and is complex since it requires several steps 
and ongoing risk factors must be identified before choosing the 
suitable hcV monitoring approach [9–11]. This approach also 
may be hampered by the fact that not all patients disclose their 
hcV risk factors during the hiV-care appointment and that 
hcV-rna monitoring is often performed with an hcV-Pcr, which 
is costly [12].
To simplify the current monitoring algorithm, a direct and 
more sensitive hcV-Pcr or hcV-cag test can be used since 
no additional confirmation (one-step diagnosis), as with alT or 
hcV-antibody, is needed and hcV can be detected earlier [13]. 
although both tests are more costly, more sensitive monitoring 
can be targeted to a very high-risk group to reduce cost [12]. re- 
infections among hiV-positive MsM are common (25%–33% 
within 2 years after cure or clearance) and associated with ongoing 
risk behaviour; therefore this patient population can be defined 
as high-risk [11,14]. in this population, intensified and/or more 
sensitive monitoring, combined with immediate Daa treatment, 
may therefore be advantageous in reducing the number of new 
hcV infections.
here, we investigated alternative monitoring strategies to intensify 
and simplify hcV diagnosis followed by immediate Daa treatment 
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both in the hiV-positive MsM population and in a targeted high-
risk hiV-positive MsM population in the netherlands. in addition, 
we estimated the cost-effectiveness of the current guidelines and 
proposed monitoring strategies over a lifetime horizon.
Methods
study design and population
The Dutch hiV epidemic is concentrated among MsM, with nearly 
70% of infected patients reporting MsM as the mode of trans-
mission, making it very similar to the hiV epidemic in other 
high-income countries [15,16]. The incidence rate of hcV among 
hiV-positive MsM is 0.6/100 persons-years [4]. in addition, 
hcV re-infections are a major concern in this population and 
occur in 25%–33% [4,11,17]. The hiV epidemic is well described 
through a national database (aThena cohort), which contains 
anonymised clinical and demographical data of >98% of patients 
in hiV care in the 27 treatment centres in the netherlands [15]. 
We adapted a previously published deterministic mathematical 
model that represents the hcV/hiV epidemic among MsM in 
the netherlands [3].
Model parametrisation and calibration
We used our previously published mathematical model represent-
ing the Dutch hiV-positive MsM epidemic, which was calibrated 
to Dutch hiV data from the aThena cohort and hcV data from 
both Dutch acute hcV in hiV studies (Dahhs 1 and 2) [3,15,18–
22]. We used the estimated Dutch MsM population size, the 
percentage of individuals co-infected with hcV, a stable hcV 
incidence rate of 1.2 per 100 person-years before Daa introduc-
tion and a stable re-infection rate of 15 per 100 person-years 
(range 8 to 26.5 per 100 person-years) [4,19,21,23,24] (Table 
1). To account for the unrestricted availability of Daas from 2015 
onwards, we validated the model’s projected incidence in 2016 
with the published Dutch hcV incidence data (0.4–1.0/100 
person-years) [49,50]. Monte carlo filtering techniques resulted 
in 132 out of 100,000 simulations that matched the Dutch hcV 
epidemic among hiV-positive MsM [51–53]. (Table s1).
Table 1. Model parameters and ranges used in hepatitis c virus transmission model
Model Parameters of HCV transmission model among Dutch MSM 
(Range/number [median], ƚ=calibrated
annual hiV diagnoses 
among MsM per time 
period
2002–2014
2015
2016
720–740 [18]
620 [15]
580 [25]
susceptible hiV-positive MsM in 2002 3800ƚ
Patients with hcV in 2002 2%–10% [19]ƚ
Mortality rate hiV patients ≥350 cD4 count 1/45 [26]*
Transmissibility of hcV 0.01–0.05ƚ
clearance rate 15%–25% [27–29]
Time to clearance 40–170 days [30]
re-infection rate 8%–26.5%, per year 
[31,32]
Time from transmission until treatment 16.5–25 weeks [33]
Patients in stages F3, F4 in 2002 10%–30%ƚ
hcc rate 2%–5% [30,34]
Monitoring parameters (diagnosed per monitoring cycle [%])
Biannual alT and annual hcV antibodies 70–100 [9,35]
hcV-Pcr 90–100 [36,37]
hcV- core antigen test 90–100 [38,39]
Treatment parameters (Range/number)
sVr, Daa F0–F3 89%–100% [40,41]
Treatment duration F0-F3 12 weeks [42]
sVr, Daa cirrhosis 80%–95% [43]
Treatment duration F4 compensated and 
decompensated
16 weeks [44]
retreatment duration F0–F3 12 weeks [42]
retreatment duration F4 compensated and 
decompensated
16 weeks [44]
Quality of life (utility score)
hiV mono-infection 0.94 [45]
acute hcV infection 0.89–0.94 [33,45]§
hcV F0–F3 stage 0.89–0.94 [37,45]§
compensated cirrhosis 0.38–0.67 [46]
Decompensated cirrhosis 0.38 [46]
hepatocellular carcinoma 0.45 [47]
Daa-based therapy 0.89–0.94 [33,45]§
Costs (€)
Doctors visit 136 [48]
hcV rna 105–225¶
hcV-core antigen 32¶
confirmation infection (Pcr price) 105–225¶
hcV genotyping 130–252¶
indirect laboratory cost 6.47–8
hcV genotype 130–252¶ 
Ultrasound of the liver 90–226¶ 
Biochemistry and liver function tests 38–46¶
F3–F4 additional costs per year** 807.88¶
Daa regimen 12 weeks 35,000¶ 
hcc: hepatocellular carcinoma; hcV: hepatitis c virus; MsM: men having sex with men; sVr: sustained virological response; Peg-iFn: pegylated interferon; rBV: 
ribavirin; Daa: direct-acting antiviral.
*  successfully treated patients who achieved viral suppression and attained a cD4+ cell count of at least 350 cells/μl within 1 year of starting antiretroviral 
therapy had a normal life expectancy, with a 35-year-old hiV-positive person estimated to live to about 80 years on average.
**  additional costs per year are based on the abdominal echo’s (hcc screening), additional doctor appointments and biochemistry.
¥ Weeks are based on the time that a patient needs to be diagnosed (16.5–25 weeks [33]) with an additional number of weeks that is ‘waited’ until a patient 
reaches possible spontaneous clearance. in the model we ‘wait’ an additional 3-3.5 months for spontaneous clearance (+/− 90 days).
§  The model considers the hcV/hiV co-infection utility score to be an interaction between the utility for hiV mono- and hcV mono-scores. The utility scores 
are varied in the sensitivity analysis.
¶  Dutch data summarised out of different academic hospitals in the netherlands.
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Our model stratifies disease progression into individuals that 
spontaneously clear the virus (15%–20% of cases [27]), three 
stages of progressive fibrosis (MeTaVir stages F0–F3) and two 
stages of cirrhosis (stage F4 subdivided in compensated and 
decompensated cirrhosis). From stage F3, F4 compensated and 
F4 decompensated cirrhosis patients can develop a hepatocellular 
carcinoma (hcc) with a rate of 2%–5%.
The rate by which hcV/hiV co-infected individuals progress from 
a particular stage of fibrosis to a more advanced stage of fibrosis 
is approximately 10% per year. This rate of progression results 
in a probability of having cirrhosis (stage F4) of 20.8% to 48.5% 
after 20 to 30 years, respectively [54] (Table s2). Due to a 
shortage of donors, liver transplantation has not been performed 
in hiV/hcV co-infected individuals in the netherlands and is 
therefore not considered in the model. We assumed that during 
hcV treatment individuals are virologically suppressed and do 
not transmit hcV to others. in our model before 2012, chroni-
cally infected patients in F2–F4 fibrosis stages were treated with 
pegylated interferon and ribavirin. Between 2012 and 2015, 
boceprevir or telaprevir, in addition to pegylated interferon and 
ribavirin, was prescribed to chronically infected patients. We 
assumed that until 2015, between 67% and 75% of patients 
were treated for 24 weeks with pegylated interferon and ribavirin 
(other patients declined treatment), in agreement with the treat-
ment guidelines that were in place. Thereafter, pegylated interferon 
was no longer considered since Daas were reimbursed for all 
stages of hcV infection in the netherlands.
in our model there are four different risk groups in which indi-
viduals have a different number of hiV-positive partners per year 
[high 20–100; medium 5–15; medium–low 1–4; low 0.1–0.9) 
(Table s2)] [52].
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Figure 1. simplified schematic representation of alternative monitoring strategies in the hepatitis c transmission model. This model is based on our previously published model [3]. 
The stage of fibrosis is represented by MeTaVir stages F0, F1, F2, F3 and F4. in our model, 15%–20% of the patients can spontaneously clear their infection. The 
current monitoring strategy is indicated in the first column (left) and based on the european aiDs clinical society guidelines [8] where all patients are monitored with 
biannual alT tests and annual hcV-antibody tests. in the next column, monitoring is either increased (time interval of 3-monthly or monthly) or alT monitoring is 
replaced with a more sensitive test such as the hcV-Pcr or hcV-cag in all hiV-positive MsM [36–39]. in the third column the alternative monitoring strategies are 
targeted to the high-risk group (previously hcV-infected hiV-positive MsM), while all other hiV-positive MsM follow the monitoring approach based on alT testing 
(current monitoring approach). all hcV-infected individuals follow the natural course of hcV when they are not treated with direct-acting antivirals. Daa: direct-acting 
antivirals; hcc: hepatocellular carcinoma; hcV: hepatitis c virus; MsM: men who have sex with men; sVr: sustained virological response. ¶ intensified monitoring from 
6-monthly time intervals to 3-monthly and monthly monitoring. ¥ More sensitive monitoring using an hcV-Pcr test or an hcV-core antigen test with higher probability 
of diagnosing hcV [36–39]
current hcV monitoring and Daa treatment in hiV care
all hiV-positive MsM undergo hcV monitoring, using a biannual 
alT test (hepatic transaminases) and an annual antibody test in 
which the model assumes that approximately 85% of the hcV 
infections are diagnosed [8,9,35]. in case of an elevated alT 
or a positive hcV antibody test, an hcV-Pcr test is used as 
a confirmation. after diagnosis, treatment is given immediately 
regardless of the possibility of clearing the infection. The model 
includes a median time of 18.1 weeks (range 16.5–25) from 
transmission until treatment initiation of acute hcV, which is 
based on published Dutch data on acute hcV infections [20]. in 
our model all individuals who have no cirrhosis receive a 12-week 
Daa treatment course. sVr rates for treatment ranged from 89% 
to 100% with a median of 94% (Table 1). if sVr is not reached, 
individuals are re-treated with a 12-week Daa course. During 
the cirrhotic stage, Daa treatment is prolonged until 16 weeks 
with sVr rates for treatment of 80%–95% [43].
alternative hcV monitoring strategies
From 2018 onwards, alternative monitoring strategies are simu-
lated in the model, which we compared with the current monitoring 
approach described in the previous paragraph (Figure 1). in the 
different monitoring strategies, we replaced alT monitoring by 
one-step diagnostics (no anti-hcV antibody and hcV-Pcr con-
firmation needed) to an hcV-Pcr or hcV-cag. Both tests are 
more sensitive and can identify 90%–100% of patients 2 weeks 
after hcV infection; however the hcV-cag is less costly than the 
hcV-Pcr [36–39] (Table 1). in addition, we intensified alT, 
hcV-Pcr and hcV-cag monitoring from 6 monthly to 3 and 
once monthly. since re-infection is common among hiV-positive 
MsM, we targeted the above-mentioned monitoring strategies 
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solely to a group of previously hcV-infected hiV-positive MsM 
(high-risk group), while the rest of the hiV-infected MsM is 
continuously monitored with alT. similar to the current monitoring 
strategy, the hcV-Pcr is used as confirmation after an elevated 
alT. additionally, the hcV-Pcr and hcV-cag do not require 
additional confirmation (Figure 1).
When monitoring is intensified, subsequently the time to treat-
ment is shortened since Daa treatment is started immediately 
after diagnosis, for example, within 3 or 1 month. in the model, 
we assume that if an hcV infection is undiagnosed, the patient 
will be retested in the next period. all monitoring strategies are 
implemented in 2018, and hcV incidence, prevalence and seque-
lae, by projecting the number of hepatocellular carcinomas avoided, 
are evaluated among hiV-positive MsM over a lifetime horizon 
of 40 years.
costs and QalY estimates
The cost-effectiveness analysis was performed from a provider 
perspective. each compartment in our deterministic model was 
assigned a costs and quality-adjusted life year (QalY) score (Table 
1). hcV monitoring and treatment costs were collected among 
the six academic Medical centers in the netherlands. Our model 
used a Daa price of €35,000 for a 12-week treatment course, 
which is varied in the sensitivity analysis. QalY weights were 
obtained from data of the Dutch hiV/hcV co-infected MsM 
cohort (Dahhs) [33]. hiV mono-infected MsM have a QalY of 
0.94 [45]. The model considers the hcV/hiV co-infection utility 
score to be an interaction between the hiV mono- and hcV 
mono-infected utility scores. hcV/hiV co-infected MsM are 
assumed to have a utility score of 0.84 during F0–F3 stage. 
QalY scores during Daa treatment remained similar. after resolv-
ing the hcV infection, the QalY score returned to that of an 
hiV mono-infected (i.e. 0.94 [45]). Both costs and QalY scores 
were discounted at 3% per year [55,56]. For this study, we used 
a willingness-to-pay threshold of €20,000 per QalY.
hiV-positive MsM are co-infected with hcV at a median age of 
40 years [33]. in addition, an hiV-positive MsM with cD4 >350 
cells/μl has a life expectancy of 80 years [26]. Therefore, we 
used a 40-year time horizon to calculate the epidemiological 
impact and economic outcomes [57]. The reported numbers are 
the median values with the corresponding interquartile range 
between brackets. Prices are notated in euros (€).
sensitivity analysis and uncertainties
We performed a one-way sensitivity analysis of the incremental 
cost-effectiveness ratios (icer), comparing the current approach, 
based on monitoring with biannual alT tests and annual hcV-
antibody tests, with the strategy in which alT is replaced with a 
more sensitive hcV-cag test and targeted to the high-risk group 
(previously hcV-infected hiV-positive MsM). several key input 
variables were varied: cost of Daas (€5000–€50,000), cost of 
a doctor appointment (increase and decrease of 50%), sponta-
neous clearance rate (5%–30%), discounting rates (0%–5%) 
and QalY score during Daa treatment (increase and decrease 
of 4%) [33,45]. after Daa treatment a patient will return to a 
QalY of 0.94, which is the same value as an individual with an 
hiV mono-infection [45]. in addition, we changed the price of 
the highly sensitive diagnostic tools (€2–€200) (hcV-Pcr and 
hcV-cag) and confirmatory test (hcV-Pcr).
recently, the hcV prevalence has been increasing among hiV 
pre-exposure prophylaxis (PreP) users, in contrast to a stabilising 
prevalence among hiV-negative MsM [58]. in addition, the 
literature suggests mixing of hcV among MsM with high-risk 
behaviour regardless of hiV status [59–61]. as specific data 
needed for calibration of hcV among hiV-uninfected MsM and 
PreP users is not fully available, we accounted for the interaction 
with hiV-uninfected MsM in our sensitivity analysis. We modelled 
an increase in the number of MsM in the high- and medium–
high-risk groups (regardless of hiV status) who are at risk for 
hcV (600 since the introduction of hiV PreP in 2015 and 6000 
in 2018 to simulate an upscale) [62]. in addition, we accounted 
for the impact of continuing transmission and interaction with 
undiagnosed hcV-infected individuals, such as hiV-negative MsM, 
hiV-positive MsM not in care and people who inject drugs (PWiDs) 
(500 individuals per year that remain undiagnosed from 2018 
onwards) combined with the influence of increasing the number 
of high-risk hiV-positive MsM.
Results
Our model projects that continuing the current monitoring 
approach results in an incidence rate of 1.1 per 1000 person-
years with a 0.24% prevalence after 20 years (Table 2).
impact of intensified and more sensitive monitoring 
strategies for all hiV-positive MsM
intensifying alT monitoring with 3-monthly time intervals reduces 
the incidence rate from 1.1 per 1000 person-years to 1.0/1000 
person-years with a 0.20% prevalence after 20 years. Further 
intensifying monitoring with monthly time intervals reduces the 
incidence rate to 0.9/1000 person-years, with a 0.16% prevalence 
(Table 2). When alT monitoring is replaced by a simplified moni-
toring strategy based on the hcV-Pcr or hcV-cag test, our 
model demonstrates that 6-monthly monitoring results in an 
incidence rate of 1.1/000 person-years and a 0.23% prevalence. 
With intensified hcV-Pcr or hcV-cag monitoring, similarly as 
seen with alT monitoring: the incidence rate declines to 0.9/1000 
person-years, with a 0.19% prevalence (20% reduction) with 
3-monthly intervals, and to 0.8/1000 person-years, with a 0.16% 
prevalence (33% reduction) with monthly intervals. intensified 
and simplified monitoring results in a maximum of 26 hccs averted 
over 20 years regardless of test used (Table 2).
impact of monitoring strategies targeted to a high-risk 
group of previously hcV-infected hiV-positive MsM
intensifying alT monitoring with time intervals of every 3 months 
and monthly after 20 years reduces the incidence rate to 1.0/1000 
person-years with a 0.22% prevalence and to 0.9/1000 person-
years with a 0.20% prevalence, respectively in a high-risk group 
of previously hcV-infected hiV-positive MsM. When alT moni-
toring is replaced by a simplified monitoring strategy based on 
the hcV-Pcr or hcV-cag test, our model projects an incidence 
rate of 1.1/1000 person-years (Table 2), with a 0.23 % preva-
lence. With intensified monitoring, the incidence rate declines to 
1.0/1000 person-years, with a 0.22% prevalence (8% reduction), 
and to 0.9/1000 person-years, with a 0.20% prevalence (17% 
reduction), when monitoring with 3-monthly and monthly time 
intervals regardless of test, respectively. intensified and simplified 
monitoring results in a maximum of seven hccs averted over 20 
years regardless of test used (Table 2).
cost-effectiveness
Our model showed that continuing alT-based hcV monitoring 
according to the current guidelines costs an overall €61.8 million 
(interquartile range 52.2–73.9) for the Dutch hcV epidemic 
among hiV-positive MsM over a lifetime horizon (Table 3). When 
monitoring with alT is increased to 3-monthly time intervals, a 
more costly scenario results, that is, €64.8 million (56.2–73.7), 
among all hiV-infected MsM. replacing the alT test results in 
higher costs of €67.1 million (58.3–75.0) and €92.2 million 
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Table 2. Different monitoring strategies with short term epidemiological impact and sequelae over a lifetime horizon
Monitoring strategies (m = months 
of monitoring interval)
Short-term HCV incidence 
per 1000 person-years
Short-term HCV 
prevalence (%) 
HCC avoided over 
a lifetime horizon
current monitoring 1.12 0.24
alT (m = 3) 0.96 0.20 15
alT (m = 1) 0.85 0.16 26
hcV-core antigen (m = 6) 1.08 0.23 1
hcV-core antigen (m = 3) 0.92 0.21 16
hcV-core antigen (m = 1) 0.78 0.20 26
hcV-Pcr (m = 6) 1.08 0.23 1
hcV-Pcr (m = 3) 0.92 0.21 16
hcV-Pcr (m = 1) 0.78 0.20 26
Targeted to the high-risk group/ 
m = months of monitoring interval
Short-term HCV incidence 
per 1000 person years
Short-term HCV 
prevalence (%)
HCC avoided over 
a lifetime horizon
alT (m = 3) 1.01 0.22 4
alT (m = 1) 0.91 0.20 7
hcV-core antigen(m = 6) 1.08 0.23 1
hcV-core antigen (m = 3) 1.01 0.22 4
hcV-core antigen (m = 1) 0.91 0.20 7
hcV-Pcr (m = 6) 1.08 0.23 1
hcV-Pcr (m = 3) 1.01 0.22 4
hcV-Pcr (m = 1) 0.91 0.20 7
short-term epidemiological impact and long-term sequelae of hcV in the form of hepatocellular carcinomas avoided when different monitoring strategies are 
applied with the alT, hcV-Pcr and hcV-cag test. in addition, monitoring is intensified from 6-monthly time intervals to 3- and monthly time intervals.
alT: alanine aminotransferase; hcc: hepatocellular carcinoma; hcV: hepatitis c virus; Pcr: polymerase chain reaction.
(82.2–100.6) when monitored every 3 months for the hcV-cag 
and hcV-Pcr, respectively. in addition, the different monitoring 
scenarios result in a similar number of QalYs and are therefore 
dominated (higher cost and similar or lower number of QalYs) 
(Table s4).
a more targeted monitoring approach towards the high-risk group 
(previously hcV-infected hiV-positive MsM) using the hcV-cag, 
however, was less costly at €60.7 million (51.9–71.6) for the total 
hcV epidemic among hiV-positive MsM (Table 3). Monitoring 
with the hcV-Pcr, as recommended by the european aiDs clinical 
society guidelines for individuals with ongoing risk behaviour, was 
slightly more expensive at €63.5 million (56.2–73.7). Monitoring 
with both the hcV-cag and hcV-Pcr test results in an increase 
of 1.4 QalYs over 40 years, compared with the current monitor-
ing approach. since the hcV-cag is less costly and results in an 
increase in QalYs, this strategy is considered cost-saving. since 
the hcV-Pcr is more costly (€63.5 million) and results in a 
similar number of QalYs gained (1.4), this is less favourable and 
considered dominated. all other monitoring interventions cost 
more and result in a similar number of QalYs; therefore, they 
are either not cost-effective or dominated (Table 3, Table s4).
sensitivity analysis
We performed a one-way sensitivity analysis to identify the factors 
that most strongly influence the cost-effectiveness ratio (Figure 
2). Our results show that the incremental cost-effectiveness ratio 
(icer) strongly depends on the price of the diagnostic and con-
firmation tool, whereas a decrease results in a more cost-saving 
strategy. The price of the Daas influences the icer to a lesser 
extent and monitoring with an hcV-cag test in a high-risk group 
remains cost-saving with a lower Daa price of €5000. in addition, 
our sensitivity analysis showed that interaction with high-risk 
hiV-negative MsM and an unidentified population, such as PWiDs 
or hiV-negative MsM not in care, increases the icer. The icer 
remains, however, cost-saving. Factors such as QalYs, cost of a 
doctor visit, clearance and discounting had a limited impact on 
the cost-effectiveness ratios.
Discussion
We used mathematical modelling to compare the impact of 
alternative hcV monitoring strategies on the hcV epidemic among 
hiV-positive MsM in the netherlands. alternative monitoring 
strategies, that is, intensified alT monitoring or monitoring with 
a hcV-Pcr or hcV-cag test, in all hiV-infected MsM results in 
a decrease of incidence and prevalence but will cost more. a 
targeted hcV-cag monitoring strategy aimed only at a high-risk 
population of previously hcV-infected hiV-positive MsM not 
only reduces the incidence and prevalence but is also less costly 
compared with the current monitoring approach. Therefore, moni-
toring with the hcV-cag in a targeted population of high-risk 
individuals is cost-saving.
This is the first study that modelled alternative monitoring 
strategies in a group of hiV-infected MsMs. in addition, this is 
the first study in which more sensitive and simplified monitoring 
was targeted to previously hcV-infected hiV-positive MsM with 
the hypothesis of a higher risk of hcV infection due to high-risk 
behaviour (re-infection rates are 25%–33%) [11,14]. currently, 
guidelines advise the use of a more sensitive diagnostic test, 
with the possibility of earlier hcV detection compared with alT 
monitoring and anti-hcV antibodies when ongoing risk factors 
are present. however, the identification of patients with ongoing 
hcV risk factors is challenging. Patients may not always disclose 
risk behaviour, such as iDU, chemsex or MsM, due to the overall 
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Table 3. cost-effectiveness in incremental cost-effectiveness ratio (icer) per alternative monitoring strategy
Monitoring 
strategies (m = time 
interval in months)
HCV 
infections 
averted 
compared 
with S1 at 
20 years
Prevalence 
reduction 
(%) at 20 
years
Cumulative 
HCCs 
avoided over 
40 years
Lifetime costs of 
the HCV epidemic 
among HIV-
positive MSM per 
million (€)
Lifetime 
QALY × 1000
Incremental 
cost (a) 
€ × 1000
Incremental 
QALYs (b)
ICER 
(a/b) × 1000
current monitoring 
strategy (s1)
61.8 (52.2–73.9) 357.98
hcV core antigen 
(m = 6) high-risk group
19 2.8 1 60.7 (51.9–71.6) 357.99 −649 1.43 cost-saving
hcV Pcr (m = 6)
high-risk group 
19 2.8 1 63.5 (54.7–100.9) 357.99 2900 0 Dominated*
alT (m = 3) high-risk 
group
57 7.9 4 64.8 (56.2–73.7) 358.00 4025 2.12 1976
hcV-core antigen 
(m = 1) high-risk group
124 15.5 7 93.6 (84.9–101.0) 358.01 27,472 2.92 9153
Table shows the short-term epidemiological impact, long-term sequelae (cumulative avoided hccs) and cost-effectiveness over a lifetime horizon of 40 years. 
The icer is calculated based on the incremental cost and incremental QalYs of the previous less costly scenario. if the incremental QalYs are equal or lower, the 
icer is considered to be dominated. costs and QalYs are calculated over a lifetime horizon of 40 years. a willingness-to-pay threshold of €20,000 is 
considered. The following monitoring strategies are dominated: alT monitoring (3-monthly and monthly) among all hiV-positive MsM and hcV-Pcr and 
hcV-cag monitoring among all hiV-infected MsM (6-monthly, 3-monthly, and monthly). For the full figure, see supplement (Table s4).
icer: incremental cost-effectiveness ratio; hcc: hepatocellular carcinoma; hcV: hepatitis c; hcV-cag: hcV-core antigen; s1: current monitoring approach based 
on alT monitoring [8].
*  When the compared strategy has equal or less QalYs compared with the previous less costly scenario.
Diagnosticum and confirmation
Price DAAs
More cost-saving Less cost-saving
High-risk HIV-negative MSM
Unidentified reservoir
QALY during treatment
Doctor’s visit
Clearance
–8
00
–6
00
–4
00
–2
00 0
Discounting
€50,000
No interaction
No interaction
+4% –4%
+50% –50%
15%–30% 5%–10%
5% 0%
Increasing and interacting
Increasing and interacting
– €454 x 1000/QALY
€5,000
€2 €200
Figure 2. One-way sensitivity analysis of the incremental cost-effectiveness ratio (icers) (€/QalY). We compared the current situation with monitoring the high-risk group with an 
hcV-cag test at 6-monthly time intervals and varied different key parameters. The bars show the range in icer if these key variables are varied. all icers are stated in 
euros. Daa: direct-acting antivirals; eacs: european aiDs clinical society; hcV-cag: hcV-core antigen; icer: incremental cost-effectiveness ratio; MsM men who have sex 
with men; QalY: quality-adjusted life year
feeling of stigmatisation and criminalisation [63,64]. Yet previously 
infected patients have a higher risk of re-infection [17]. Our 
model projected that a more stratified approach among previously 
hcV-infected individuals resulted in a reduction of the overall cost 
of the hcV epidemic among hiV-positive MsM, despite the use 
of a more costly diagnostic test compared with alT monitoring.
Moreover, a more sensitive test, such as the hcV-Pcr or hcV-cag 
test, not only results in early diagnosis of hcV but also accelerates 
the result and simplifies hcV monitoring. While elevated alT or a 
positive anti-hcV antibody requires additional confirmation, an 
hcV-Pcr or hcV-cag is a one-step approach. One step-diagnostics 
help to avoid losing patients out of the hcV care cascade [65]. 
This is less likely for hiV-infected MsM, who are integrated in hiV 
care, but more essential to other risk groups as hiV-uninfected 
MsM or PWiDs. in addition, a more sensitive monitoring approach 
is more feasible compared with intensified monitoring since the 
latter requires additionally hospital appointments.
The results of this study are of importance since the WhO rec-
ommends using cost-effectiveness analysis to determine the best 
value for money. in addition, there is a lack of financial resources 
towards testing and treatment of hcV [5,66]. in the past years 
most focus has been on the cost of Daas and the cost-effectiveness 
of Daas while little focus has been placed on the cost and cost-
effectiveness of diagnostics. still, many individuals are unaware 
of their hcV infection, and test and treat in high-risk population 
showed tremendous epidemiological and cost benefits [3,66]. 
Our model showed that when monitoring is targeted properly to 
the right risk groups, cost can be avoided and benefits are gained.
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To diagnose 90% of the individuals living with hcV by 2030, a 
target of the WhO, it important to assess the price of the diag-
nostic test [5]. currently, the hcV-Pcr is more costly (€105–€225) 
compared with the hcV-cag test (€32), but both tests have a 
similar performance [38,39]. Therefore, the hcV-cag test can 
play a significant role in hcV diagnosis in high-income settings 
because it has a more affordable price and similar performance 
to the hcV-Pcr. Moreover, our model showed that hcV-Pcr 
monitoring in a high-risk group, as recommended by the guide-
lines, is not cost-effective, based on the current hcV-Pcr pricing 
[8]. nevertheless, the current overall price of hcV diagnosis is 
very costly for many countries, especially in low- and middle-
income countries, where huge numbers require hcV screening 
and monitoring.
in the netherlands, hcV incidence among hiV-infected MsM 
already declined significantly after immediate Daa therapy [3,4]. 
Therefore, the next step towards the WhO elimination goal is 
hcV micro-elimination in the hiV-infected MsM population, the 
major transmitters of new hcV infections in the netherlands 
[21,67,68]. consequently, the impact of intensified testing is 
rather small. Unfortunately, our model showed that, even with 
monthly hcV monitoring followed by immediate Daa treatment, 
micro-elimination in this population is not obtained by 2030. 
another modelling study from salazar-Vizcaya et al. showed 
that risk reduction in combination with an upscaling of Daa 
therapy could result in micro-elimination [69]. Our model also 
indicated that a reduction in risk behaviour is needed to reach 
elimination by 2030 (data not shown). This information highlights 
the need for harm reduction programmes in the hiV-infected MsM 
population.
a key strength of our model is that we have access to data of 
the well-monitored Dutch hiV epidemic and that we could calibrate 
our data to new hcV diagnoses among people living with hiV 
in the netherlands [4,15]. Therefore, our model is calibrated to 
complete and accurate data on the annual number of (newly) 
diagnosed hiV-positive MsM, which allows us to make accurate 
predictions on the epidemiological effect of alternative monitoring 
strategies and the possibility of achieving micro-elimination [3].
Our model has several limitations. First, since specific data regarding 
hcV transmission and interaction of hcV with hiV-negative MsM 
was not available, our model considered only hcV transmission 
among hiV-positive MsM, although hcV transmission is found 
less frequently among hiV-negative MsM [61,70,71]. hiV (PreP 
usage could increase hcV incidence, as reported by some studies. 
This could result in hcV begin expanded among hiV uninfected 
MsM, with high-risk behaviour [61,72]. Therefore, we accounted 
for the effect of interaction between the hiV-infected MsM and 
hiV-uninfected MsM population in our sensitivity analysis. This 
shows that regardless of an increased hcV incidence in the hiV-
uninfected MsM population, hcV-cag monitoring in a high-risk 
population remains cost-saving. second, data regarding the number 
of individuals who acquire hcV outside the netherlands are limited. 
in addition, interaction with populations who are not in care, 
for example PWiDs or “illegal” PreP users, might result in new 
hcV infections among hiV-positive MsM [67,68]. To account 
for interaction with an unidentified and untreated population 
(transmission outside the netherlands, PWiDs and “illegal” PreP 
users), we conducted a sensitivity analysis that showed a cost 
increase but remained a cost-saving strategy.
Conclusion
Our model showed that the hcV epidemic among hiV-positive MsM 
can be reduced in a cost-saving manner by simplifying monitoring 
strategies using targeted one-step diagnostics with the hcV-cag. 
however, since we are aiming at elimination, the epidemiological 
impact is rather small. nevertheless, the hcV-cag test can play a 
significant role in hcV diagnosis in high-income settings because 
it has an affordable price and similar performance to hcV-Pcr. in 
addition, in the past years, most focus has been on the cost of 
Daas and very little focus has been placed on the cost of diag-
nostics. currently, using an hcV-Pcr when risk factors are present, 
as recommended by the guidelines, is not cost-effective because 
hcV-Pcr pricing is high. Therefore, the next step towards elimina-
tion is to simplify diagnostics and lower the prices of diagnostic 
tools. Unfortunately, despite intensified monitoring strategies, our 
model does not predict micro-elimination of hcV before 2030 
and indicates the need for harm reduction programmes.
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S1 Model description and calibration
The model is seeded in 2002 with 3800 hiV-infected men who 
have sex men (MsM) of whom 3%–10% were co-infected with 
hepatitis c (hcV). The state variables are described in Table 1 
and Table s2. all hcV transmission equations are described in 
Popping s et al [1]. Our model includes four activity groups [i] 
based on the partner acquisition rate change per year: class 1 
(high) in which individuals have 20–100 hiV-infected partners 
per year, class 2 (medium) with 5–15 partners, class 3 (medium–
low) with 1–4 partners and class 4 (low) with 0.1–0.9 partners.
The model includes seven hcV infection stages: one stage includ-
ing patients who are infected but will clear hcV and five stages 
of increasing severity of fibrosis (MeTaVir stages F0, F1, F2, 
F3 and F4). stage F4 represents cirrhosis and is subdivided into 
compensated cirrhosis (F4c) and decompensated cirrhosis (F4D). 
stage F0 makes a distinction between patients who are diag-
nosed in a timely manner and who initiated treatment, patients 
who are not diagnosed, patients who are diagnosed but would 
have cleared treatment and patients who refuse treatment. in 
addition, the model accounts for the cost of overtreatment of 
patients who are put on treatment but would have cleared their 
infection.
Patients are monitored in the model when they are in the sus-
ceptible stage, considered susceptible (infection is not diagnosed 
due to a false-negative test), susceptible after a previous hcV 
infection and considered susceptible after a previous hcV infection. 
hcV monitoring is preformed with several tests, hcV antibodies, 
alT, hcV-Pcr and the hcV-core antigen depending on the sce-
nario. in addition, monitoring intervals vary from every 6 months, 
every 3 months, and monthly. We targeted monitoring interven-
tions to a high-risk group of patient who previously were infected 
with hcV, while all other hiV-infected MsM are monitored with 
Table S1 
Parameter used to accept 
simulations
Values 
accepted
number of hiV-hcV co-infections in 
2014 (n)
450–850 [2]
annual number of new hiV-hcV 
co-infections (2014) (n)
100–150 [3]
incidence rate in 2012–2014 (per 
1000 person-years)
11–13 per [4]
incidence rate after Daa roll-out 2016 
(per 1000 person-years)
4–10 per 1000 [5,6]
re-infection rate in 2014 (% per year) 8–26.5 [7,8]
Daa: direct-acting antivirals; hcV: hepatitis c virus.
biannual alT measurements and hcV antibodies. as soon as a 
patient is diagnosed, Daa therapy is started.
Treatment was calibrated as follows: in the model until 2015, 
between 67% and 75% of patients with hiV who were acutely 
infected with hcV were treated for 24 weeks with pegylated inter-
feron (Peg-iFn) and ribavirin (other patients declined treatment). 
Before 2012, chronically infected patients in MeTaVir stages 
F2–F4 were also treated with (Peg-iFn) and ribavirin. Between 
2012 and 2015, boceprevir or telaprevir, in addition to pegylated 
interferon and ribavirin, was prescribed to chronically infected 
patients. in 2015, unrestricted Daas became available, and we 
calibrated to this effect, using the Dutch incidence rates in 2016. 
From 2018 onwards, the model compares the epidemiological and 
economic impact of different monitoring strategies as described 
in the previous paragraph.
Parameters used for Monte carlo filtering technique to 
calibrate our model
Variables used to calibrate and accept simulations
Number of MSM diagnosed with HIV
2004 2006 2008 2010 2012 2014
4000
6000
8000
10000
12000
Simulations (median)
Dutch data
Year
N
u
m
b
er
comparison of the projected number of MsM who are diagnosed 
with hiV (black bullets and line) and the actual number of MsM 
diagnosed as reported by the Dutch hiV Monitoring Foundation.
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comparison of the incidence rate in the Dutch population over 
time and the median simulations of our model. at T = 2014, the 
first Daas were introduced in the netherlands for F2/F3 patients 
and treatment in clinical trials. in 2015, Daas became unrestricted, 
and in 2016 new incidence data were available [9].
S2 Model parameters used in hepatitis C 
transmission model
Table S2 
Parameters of epidemic among HIV-positive MSM Range
Annual new sexual partner 
per risk group [i] (n)
high
Medium
Medium-low
low
20–100§
5–15
1–4
0.1–0.9
Proportion per risk group high
Medium
Medium-low
low
–0.14§
–0.2
0–0.3
0.4–0.9
rate of assortative mixing 0–0.8§
Patients in stages F3, F4 in 2002 (%) 10%–30§
Life Expectancy and mortality
life expectancy hiV-infected men cD4 >350 
(years)
80 [10]
life expectancy hiV/hcV co- infected (F0–F3 
stage) (years)
80
life expectancy hiV/hcV co-infected 
compensated cirrhosis (per year)
0.024–0.055 [11]
life expectancy hiV/hcV decompensated 
cirrhosis (per year)
0.019–0.35 [11] 
Annual disease progression
F0 to F1 0.098–0.122 [12]
F1 to F2 0.095–0.140 [12]
F2 to F3 0.097–0.159 [12]
F3 to compensated cirrhosis 0.098–0.135 [12]
compensated to decompensated cirrhosis 0.029–0.063 [11]
compensated to decompensated cirrhosis 0.029–0.063 [11]
cirrhosis to hepatocellular carcinoma 0.01–0.03 [13]
liver transplantations in hcV/hiV co-infected 
individuals 
0 
Cost
cost of hepatocellular carcinoma (including 
hospitalisation, treatment, surgery and care until 
death) 
€67.591–€233.573 
per patient [14,15]
hcV: hepatitis c virus; F0–F3 MeTaVir score.
§ calibrated.
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Table S4 
Monitoring strategies Lifetime costs per million (€) Lifetime QALY × 1000 ICER (a/b) × 1000
Current monitoring strategy (S1) 61.8 (52.2–73.9) 358
hcV-core antigen(t = 6) risk group 61.0 (52.2–72.8) 358 cost-saving
hcV-Pcr (t = 6) risk group 63.8 (55.1–75.7) 358 Dominated
alT (t = 3) risk group 64.8 (56.2–73.7) 358 1689
hcV-core antigen(t = 3) risk group 67.1 (58.3–75.0) 358 Dominated
hcV-core antigen (t = 6) 68.3 (59.9–80.8) 358 Dominated
alT (t = 1) risk group 88.4 (79.5–95.6) 358 Dominated
hcV-Pcr (t = 3) risk group 92.2 (82.2–100.6) 358 Dominated
hcV-core antigen (t = 1) risk group 93.8 (85.3–101.5) 358 9239
hcV-Pcr (t = 6) 121.8 (114.1–134.0) 358 Dominated
hcV-Pcr (t = 1) risk group 165.5 (156.4–178.1) 358 Dominated
alT (t = 3) 169.6 (163.5–175.9) 358 Dominated
hcV-core antigen (t = 3) 216.1 (210.1–223.8) 358 Dominated
alT (t = 1) 650.0 (645.3–655.1) 358 Dominated
hcV-Pcr (t = 3) 688.9 (682.4–695.7) 358 Dominated
hcV-core antigen (t = 1) 761.6 (756.6–758.4) 358 Dominated
hcV-Pcr (t = 1) 2180 (2175–2186) 358 Dominated
icer: incremental cost-effectiveness ratio; QalY: quality-adjusted life year.
in this figure the short-term epidemiological impact of the alter-
native monitoring strategies is projected. in the left panel the 
incidence and prevalence of hcV among hiV-infected MsM is 
projected when the alternative monitoring strategies apply to all 
hiV-infected MsM. since this increases the cost of the total hcV 
epidemic, these strategies are not cost-effective. in the right 
panels the incidence and prevalence of hcV among hiV-infected 
MsM is projected when alternative monitoring strategies are 
targeted to a high-risk group of hiV-infected MsM who were 
previously hcV infected. This group has a high risk, with 20%–25% 
of becoming re-infected. Targeted testing with the hcV-core 
antigen costs less and has some impact on the incidence and 
prevalence. Therefore, this strategy is considered cost-saving.
S4 Outcome cost-effectiveness analysis
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